ReviewDiagnostics (Basel, Switzerland)2025
Familial Mediterranean Fever; Recent Advances, Future Prospectives.
Review in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Seasonal and geographic variations in vitamin D levels among patients with familial Mediterranean fever: a systematic review and meta-analysis.Clinical rheumatology · 2026Pooled it
- Effectiveness of colchicine preparation switching in pediatric colchicine-resistant familial Mediterranean fever: a real-world study.European journal of pediatrics · 2026Article
- Anti-citrullinated Protein Antibody-positive Arthralgia Associated with an L110P-E148Q Double Heterozygote: A Case-based Review.Internal medicine (Tokyo, Japan) · 2026Review
- Exertional leg pain is associated with ıncreased disease activity and musculoskeletal ınvolvement, but not MEFV genotype, in familial Mediterranean fever.Irish journal of medical science · 2026Article
- Sleep Quality and Depressive Symptoms in Clinically Stable Pediatric Familial Mediterranean Fever: Associations with Disease Severity and Developmental Factors.Children (Basel, Switzerland) · 2026Article
- Before calling it FMF: MEFV variants of uncertain significance in autoinflammatory disease.Rheumatology (Oxford, England) · 2026Article
- Evidence of the role of Midkine and Pleiotrophin in the pathogenesis of Familial Mediterranean Fever.European journal of pediatrics · 2026Article
- Persistent Fever as the Solitary Manifestation of Familial Mediterranean Fever: A Case Report.Cureus · 2026Article
- Impact of Colchicine Therapy on Ventriculoarterial Coupling in Familial Mediterranean Fever: A Cross-Sectional Study.Journal of clinical medicine · 2025Article
- Vasculitis as an indicator of disease severity in familial Mediterranean fever.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial Mediterranean Fever (FMF) is the prototype and most common autoinflammatory disease that is particularly frequent in populations originating from the Mediterranean basin. It is characterized by episodes of recurrent inflammation lasting 2-3 days. Colchicine is the mainstay therapy, which decreases the number of attacks and eventually prevents amyloidosis, the most worrisome complication of uncontrolled FMF. It is an autosomal recessive disease. The high rate of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.